GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (OTCPK:IPHYF) » Definitions » Notes Receivable

IPHYF (Innate Pharma) Notes Receivable : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Innate Pharma Notes Receivable?

Innate Pharma's Notes Receivable for the quarter that ended in Dec. 2024 was $0.00 Mil.


Innate Pharma Notes Receivable Historical Data

The historical data trend for Innate Pharma's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innate Pharma Notes Receivable Chart

Innate Pharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Innate Pharma Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Innate Pharma Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Innate Pharma Notes Receivable Related Terms

Thank you for viewing the detailed overview of Innate Pharma's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Innate Pharma Business Description

Address
117, Avenue de Luminy, Marseille, FRA, 13009
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.